Risk factors for grade II-IV acute GVHD
| Risk factor . | Hyperacute GVHD . | Other acute GVHD Univariate . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate . | Multivariate . | Univariate . | Multivariate . | |||||||||
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Patient age | ||||||||||||
| Older than 47 y | 0.8 | 0.5-1.2 | .3 | — | — | — | 1.1 | 0.8-1.5 | .5 | — | — | — |
| 47 y or younger | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Patient sex | — | — | ||||||||||
| Female | 0.9 | 0.5-1.4 | .5 | — | — | 0.9 | 0.7-1.2 | .4 | — | — | — | |
| Male | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Donor/patient sex | ||||||||||||
| Female/Male | 1.5 | 0.9-2.5 | .09 | 1.7 | 1.1-2.9 | .03 | 1.1 | 0.8-1.5 | .7 | — | — | — |
| Other | 1.0 | Reference | — | 1.0 | Reference | — | 1.0 | Reference | — | — | — | |
| Disease status at transplantation | ||||||||||||
| Remission | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Not in remission | 0.9 | 0.6-1.4 | .7 | — | — | — | 1.2 | 0.9-1.7 | .2 | — | — | — |
| Donor type | ||||||||||||
| Mrel | 1.0 | Reference | — | 1.0 | Reference | — | 1.0 | Reference | 1.0 | Reference | — | |
| MUD | 2.2 | 1.3-3.7 | .002 | 2.3 | 1.4-3.9 | .001 | 1.5 | 1.13-2.1 | .006 | 1.6 | 1.2-2.1 | .004 |
| MMrel | 4.1 | 2.1-7.7 | < .001 | 3.6 | 1.9-6.9 | < .001 | 1.9 | 1.2-3.7 | .01 | 1.9 | 1.2-3.2 | .011 |
| Conditioning regimen | ||||||||||||
| Reduced intensity | 1.0 | Reference | — | — | 1.0 | Reference | — | — | — | |||
| High-dose chemotherapy | 3.3 | 1.8-6.2 | < .001 | — | — | — | 1.3 | 0.97-1.8 | .08 | — | — | — |
| TBI | 3.4 | 1.6-7.4 | .002 | — | — | — | 1.4 | 0.9-2.3 | .1 | — | — | — |
| HDC/HDC+TBI vs reduced intensity | 3.3 | 1.8-6.1 | < .001 | 3.8 | 2.0-7.0 | < .001 | 1.3 | 1.0-1.8 | .05 | — | — | |
| Diagnosis | ||||||||||||
| Lymphoid | 0.9 | 0.6-1.5 | .8 | — | — | — | 0.8 | 0.6-1.1 | .2 | — | — | |
| Myeloid | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Multiple myeloma | 0.3 | 0.05-2.5 | .3 | — | — | — | 1.0 | 0.5-2.0 | .9 | — | — | — |
| Solid tumor | 2.0 | 0.9-4.8 | .1 | — | — | — | 0.7 | 0.3-1.6 | .4 | — | — | — |
| Other | 1.8 | 0.4-7.5 | .4 | — | — | — | 0.6 | 0.1-2.3 | .4 | — | — | — |
| Number of prior chemotherapy lines | ||||||||||||
| 5 or fewer | 1.0 | Reference | — | 1.0 | Reference | — | 1.0 | Reference | — | — | — | |
| More than 5 | 2.1 | 1.04-4.2 | .04 | 3.1 | 1.5-6.4 | .002 | 0.9 | 0.5-1.8 | .97 | — | — | |
| Prior autologous transplantation | ||||||||||||
| No | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Yes | 0.8 | 0.3-1.9 | .6 | — | — | — | 0.5 | 0.3-0.9 | .03 | 0.4* | 0.2-0.8 | .01 |
| Cell source in Mrel grafts | ||||||||||||
| BM | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| PB | 1.3 | 0.5-3.9 | .6 | — | — | — | 1.5 | 0.8-2.5 | .2 | — | — | — |
| Risk factor . | Hyperacute GVHD . | Other acute GVHD Univariate . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate . | Multivariate . | Univariate . | Multivariate . | |||||||||
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Patient age | ||||||||||||
| Older than 47 y | 0.8 | 0.5-1.2 | .3 | — | — | — | 1.1 | 0.8-1.5 | .5 | — | — | — |
| 47 y or younger | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Patient sex | — | — | ||||||||||
| Female | 0.9 | 0.5-1.4 | .5 | — | — | 0.9 | 0.7-1.2 | .4 | — | — | — | |
| Male | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Donor/patient sex | ||||||||||||
| Female/Male | 1.5 | 0.9-2.5 | .09 | 1.7 | 1.1-2.9 | .03 | 1.1 | 0.8-1.5 | .7 | — | — | — |
| Other | 1.0 | Reference | — | 1.0 | Reference | — | 1.0 | Reference | — | — | — | |
| Disease status at transplantation | ||||||||||||
| Remission | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Not in remission | 0.9 | 0.6-1.4 | .7 | — | — | — | 1.2 | 0.9-1.7 | .2 | — | — | — |
| Donor type | ||||||||||||
| Mrel | 1.0 | Reference | — | 1.0 | Reference | — | 1.0 | Reference | 1.0 | Reference | — | |
| MUD | 2.2 | 1.3-3.7 | .002 | 2.3 | 1.4-3.9 | .001 | 1.5 | 1.13-2.1 | .006 | 1.6 | 1.2-2.1 | .004 |
| MMrel | 4.1 | 2.1-7.7 | < .001 | 3.6 | 1.9-6.9 | < .001 | 1.9 | 1.2-3.7 | .01 | 1.9 | 1.2-3.2 | .011 |
| Conditioning regimen | ||||||||||||
| Reduced intensity | 1.0 | Reference | — | — | 1.0 | Reference | — | — | — | |||
| High-dose chemotherapy | 3.3 | 1.8-6.2 | < .001 | — | — | — | 1.3 | 0.97-1.8 | .08 | — | — | — |
| TBI | 3.4 | 1.6-7.4 | .002 | — | — | — | 1.4 | 0.9-2.3 | .1 | — | — | — |
| HDC/HDC+TBI vs reduced intensity | 3.3 | 1.8-6.1 | < .001 | 3.8 | 2.0-7.0 | < .001 | 1.3 | 1.0-1.8 | .05 | — | — | |
| Diagnosis | ||||||||||||
| Lymphoid | 0.9 | 0.6-1.5 | .8 | — | — | — | 0.8 | 0.6-1.1 | .2 | — | — | |
| Myeloid | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Multiple myeloma | 0.3 | 0.05-2.5 | .3 | — | — | — | 1.0 | 0.5-2.0 | .9 | — | — | — |
| Solid tumor | 2.0 | 0.9-4.8 | .1 | — | — | — | 0.7 | 0.3-1.6 | .4 | — | — | — |
| Other | 1.8 | 0.4-7.5 | .4 | — | — | — | 0.6 | 0.1-2.3 | .4 | — | — | — |
| Number of prior chemotherapy lines | ||||||||||||
| 5 or fewer | 1.0 | Reference | — | 1.0 | Reference | — | 1.0 | Reference | — | — | — | |
| More than 5 | 2.1 | 1.04-4.2 | .04 | 3.1 | 1.5-6.4 | .002 | 0.9 | 0.5-1.8 | .97 | — | — | |
| Prior autologous transplantation | ||||||||||||
| No | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| Yes | 0.8 | 0.3-1.9 | .6 | — | — | — | 0.5 | 0.3-0.9 | .03 | 0.4* | 0.2-0.8 | .01 |
| Cell source in Mrel grafts | ||||||||||||
| BM | 1.0 | Reference | — | — | — | — | 1.0 | Reference | — | — | — | |
| PB | 1.3 | 0.5-3.9 | .6 | — | — | — | 1.5 | 0.8-2.5 | .2 | — | — | — |
HDC indicates high-dose chemotherapy; —, not applicable.
Effect among patients receiving reduced-intensity conditioning.